Aztreonam, the First Monobactam
Authors: RICHARD J. DUMA
Journal: Annals of Internal Medicine (1987)

Editorials1 May 1987Aztreonam, the First MonobactamRICHARD J. DUMA, M.D., Ph.D.RICHARD J. DUMA, M.D., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-106-5-766 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince Fleming's Discovery of penicillin almost 50 years ago (2), several closely related types of beta lactams have emerged, each with minor chemical alterations in structures attached to the nucleus that produce profound changes in the biologic properties of the molecule. Chemically, all beta lactams have two characteristics in common: they have bioactive beta lactam rings and they are fused bicyclic compounds. However, now a new and very different class of beta lactams, the monobactams, is entering the antibiotic arena. Although they still have the beta lactam ring, the monobactams are not fused bicyclic compounds.Monobactams are naturally occurring, and,...References1. BERGER S. Apocalypse [Letter]. N Engl J Med. 1985;312:1394-5. CrossrefMedlineGoogle Scholar2. FLEMING A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226-36. Google Scholar3. SYKES R, CIMARUSTI C, and BONNER D. Monocyclic beta-lactam antibiotics produced by bacteria. Nature. 1981;291:489-91. CrossrefMedlineGoogle Scholar4. BREUER H, CIMARUSTI T, DENZEL T, KOSTER W, SLUSARCHYK W, and TREUNER U. Monobactams—structure-activity relationships leading to SQ 26,776. J Antimicrob Chemother. 1981;8(suppl E):21-8. CrossrefMedlineGoogle Scholar5. NEU H and LABTHAVIKUL P. Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother. 1981;8(suppl E):111-22. CrossrefMedlineGoogle Scholar6. SYKES R and BONNER D. Discovery and development of the monobactams. Rev Infect Dis. 1985;7(suppl 4):S579-93. CrossrefMedlineGoogle Scholar7. SCULLY B and NEU H. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med. 1985;78:251-61. CrossrefMedlineGoogle Scholar8. SCHENTAG J, VARI A, and WINSLADE N. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med. 1985;78(suppl 2A):34-41. CrossrefMedlineGoogle Scholar9. JACOBUS N, FERREIRA M, and BARZA M. In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother. 1982;22:832-8. CrossrefMedlineGoogle Scholar10. SANDERS C and SANDERS W Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983;5:639-48. CrossrefMedlineGoogle Scholar11. DE VRIES-HOSPERS H, WELLING G, SWABB E, and VAN DER WAAIJ D. Selective decontamination of the digestive tract with aztreonam: a study of 10 healthy volunteers. J Infect Dis. 1984;150:636-42. CrossrefMedlineGoogle Scholar12. JONES P, BODEY G, SWABB E, and ROSENBAUM B. Effect of aztreonam on throat and stool flora of cancer patients. Antimicrob Agents Chemother. 1984;26:941-3. CrossrefMedlineGoogle Scholar13. FERNANDES P, SANTORO D, KAO C, BONNER D, and SYKES R. Antibiotic-associated colitis—side effect not produced with azthreonam in the hamster model [Abstract 136]. In: Program and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: American Society of Microbiology; 1982. Google Scholar14. SAXON A, HASSNER A, SWABB E, WHEELER B, and ADKINSON N Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis. 1984;149:16-22. CrossrefMedlineGoogle Scholar15. ADKINSON N, SAXON A, SPENCE M, and SWABB E. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis. 1985;7(suppl 4):S613-21. CrossrefMedlineGoogle Scholar16. NEWMAN T, DRESLINSKI G, and TADROS S. Safety profile of aztreonam in clinical trials. Rev Infect Dis. 1985;7(suppl 4):S648-55. CrossrefMedlineGoogle Scholar17. RODRIGUEZ J, RAMIREZ-RONDA C, and NEVAREZ M. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1985;27:246-51. CrossrefMedlineGoogle Scholar18. SATTLER F, MOYER J, SCHRAMM M, LOMBARD J, and APPLEBAUM P. Aztreonam compared with gentamicin for treatment of serious urinary tract infections. Lancet. 1984;1:1315-8. CrossrefMedlineGoogle Scholar19. BIROLINI D, MORAES M, and DE SOUZA D. Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections. Rev Infect Dis. 1985;7(suppl 4):S724-8. CrossrefMedlineGoogle Scholar20. YOUNG L. The new fluorinated quinolones for infection prevention in acute leukemia [Editorial]. Ann Intern Med. 1987;106:144-6. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: RICHARD J. DUMA, M.D., Ph.D.Affiliations: Medical College of Virginia Division of Infectious Diseases Richmond, Virginia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byResistance to Antimicrobial Agents: From Bacteria to YeastChromobacterium violaceum: A Review of an Unexpected ScourgeCopper‐Catalyzed Oxidative Benzylic C(sp 3 )−H Cyclization for the Synthesis of β‐LactamsAntibacterial and β-Lactamase Inhibitory Activity of Monocyclic β-LactamsIodine(III)-Catalyzed Cascade Reactions Enabling a Direct Access to β-Lactams and α-Hydroxy-β-amino AcidsCH Bond Activation as a Powerful Tool in the Construction of Biologically Active Nitrogen-Containing HeterocyclesChromobacterium violaceum Septicaemia and Urinary Tract Infection: Case Reports from a Tertiary Care Hospital in South IndiaOther Gram-Negative and Gram-Variable BacilliAccess to β-Lactams by Enantioselective Palladium(0)-Catalyzed C(sp 3 )H AlkylationAccess to β-Lactams by Enantioselective Palladium(0)-Catalyzed C(sp 3 )H AlkylationData-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and DiscoveryNonpigmented Chromobacterium violaceum bacteremic cellulitis after fish biteOther Gram-Negative and Gram-Variable BacilliMISCELLANEOUS NON-ENTEROBACTERIACEAE FERMENTATIVE BACILLINon-chromogenic chromobacterium violaceum bacteremiaNear‐fatal septicaemia with Chromobacterium violaceum 1 May 1987Volume 106, Issue 5Page: 766-767KeywordsAntibioticsBiologicsPenicillin ePublished: 1 December 2008 Issue Published: 1 May 1987 PDF downloadLoading ...